Fig. 4
a ICC staining of pCDC25CSer216 and P53 in HEY and BT-549 before and after CoCl2 treatment (200×). pCDC25CSer216 in (a) HEY control cells, (b) HEY PGCCs with daughter cells, (c) BT-549 control, and (d) BT-549 PGCCs with daughter cells. P53 in (e) HEY control, (f) HEY PGCCs with daughter cells, (g) BT-549 control, and (h) BT-549 PGCCs and daughter cells. b CDC25C, pCDC25CSer216, pCDC25CSer198, CHK1, CHK2, PLK1, Aurora A, P53 expression in HEY and BT-549 control cells and PGCCs before and after MG-132 treatment. c (a) Cytoplasmic and nuclear expression of pCDC25CSer216 and pCDC25CSer198 in HEY and BT-549 control cells and PGCCs after MG-132 treatment. (b) ICC staining showing the subcellular localization of pCDC25CSer216 in HEY and BT-549 PGCCs with budding cells after MG-132 treatment (400×). d Columnar percentage plot showing the ratio of cells at G1, S, and G2 stages of cell cycle in HEY and BT-549 cells. (a) The ratio of cells at G1, S, and G2 stages in HEY control and PGCCs with daughter cells before and after CoCl2 treatment. (b) The ratio of cells at G1, S, and G2 stages in HEY control and PGCCs with daughter cells before and after CDC25C knockdown. (c) The ratio of cells at G1, S, and G2 stages in BT-549 control and PGCCs with daughter cells before and after CDC25C knockdown. (d) The ratio of cells at G1, S, and G2 stages in HEY control and PGCCs with daughter cells before and after MG132 treatment. (e) The ratio of cells at G1, S, and G2 stages in BT-549 control and PGCCs with daughter cells before and after MG132 treatment. e The results of kinase activity assay in vitro. (a) HEY control cells and PGCCs with budding. (b) BT-549 control cells and PGCCs with budding. Treatment: Cells treated with CoCl2. MG: Cells were treated with MG-132. 1531si: siRNA CDC25C-1531